|Circulating tumor cells, disease progression, and survival in metastatic breast cancer|
M Cristofanilli, GT Budd, MJ Ellis, A Stopeck, J Matera, MC Miller, ...
New England Journal of Medicine 351 (8), 781-791, 2004
|Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer|
M Cristofanilli, DF Hayes, GT Budd, MJ Ellis, A Stopeck, JM Reuben, ...
Journal of clinical oncology 23 (7), 1420-1430, 2005
|Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival|
DF Hayes, M Cristofanilli, GT Budd, MJ Ellis, A Stopeck, MC Miller, ...
Clinical Cancer Research 12 (14), 4218-4224, 2006
|Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer|
GT Budd, M Cristofanilli, MJ Ellis, A Stopeck, E Borden, MC Miller, ...
Clinical Cancer Research 12 (21), 6403-6409, 2006
|Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer|
SE Jones, J Erban, B Overmoyer, GT Budd, L Hutchins, E Lower, ...
Journal of Clinical Oncology 23 (24), 5542-5551, 2005
|Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR|
DG Hicks, SM Short, NL Prescott, SM Tarr, KA Coleman, BJ Yoder, ...
The American journal of surgical pathology 30 (9), 1097-1104, 2006
|Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.|
CW Taylor, S Green, WS Dalton, S Martino, D Rector, JN Ingle, NJ Robert, ...
Journal of Clinical Oncology 16 (3), 994-999, 1998
|Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study|
S Seicean, A Seicean, JC Plana, GT Budd, TH Marwick
Journal of the American College of Cardiology 60 (23), 2384-2390, 2012
|Estrogen receptor mutations in tamoxifen-resistant breast cancer|
PS Karnik, S Kulkarni, XP Liu, GT Budd, RM Bukowski
Cancer research 54 (2), 349-353, 1994
|Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA. 27—a randomized controlled phase III trial|
PE Goss, JN Ingle, KI Pritchard, MJ Ellis, GW Sledge, GT Budd, ...
Journal of clinical oncology 31 (11), 1398, 2013
|Novel prognostic immunohistochemical biomarker panel for estrogen receptor–positive breast cancer|
BZ Ring, RS Seitz, R Beck, WJ Shasteen, SM Tarr, MCU Cheang, ...
Journal of Clinical Oncology 24 (19), 3039-3047, 2006
|Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure|
S Seicean, A Seicean, N Alan, JC Plana, GT Budd, TH Marwick
Circulation: Heart Failure 6 (3), 420-426, 2013
|Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer|
NC Levitt, FALM Eskens, KJ O’Byrne, DJ Propper, LJ Denis, SJ Owen, ...
Clinical Cancer Research 7 (7), 1912-1922, 2001
|Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of …|
MJ Ellis, VJ Suman, J Hoog, R Goncalves, S Sanati, CJ Creighton, ...
Journal of Clinical Oncology 35 (10), 1061, 2017
|The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy|
Y Zhang, AM Sieuwerts, M McGreevy, G Casey, T Cufer, A Paradiso, ...
Breast cancer research and treatment 116 (2), 303-309, 2009
|Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial.|
RL Miller, RM Bukowski, GT Budd, J Purvis, JK Weick, K Shepard, ...
Journal of Clinical Oncology 6 (5), 880-888, 1988
|Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre …|
WD Tap, Z Papai, BA Van Tine, S Attia, KN Ganjoo, RL Jones, S Schuetze, ...
The lancet oncology 18 (8), 1089-1103, 2017
|Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma|
RM Bukowski, W Sharfman, S Murthy, P Rayman, R Tubbs, J Alexander, ...
Cancer research 51 (16), 4199-4205, 1991
|NCCN guidelines insights: bone cancer, version 2.2017|
JS Biermann, W Chow, DR Reed, D Lucas, DR Adkins, M Agulnik, ...
Journal of the National Comprehensive Cancer Network 15 (2), 155-167, 2017
|Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis|
R Van Stolk, G Stoner, WL Hayton, K Chan, B DeYoung, L Kresty, ...
Clinical cancer research 6 (1), 78-89, 2000